G. Cologni

发表

Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens

F. T. P. Group, C. Torti, G. Carosi, 2007, Drug safety.

Early Virological Failure after Tenofovir + Didanosine + Efavirenz Combination in HIV-Positive Patients upon Starting Antiretroviral Therapy

A. Antinori, C. Torti, G. Carosi, 2005, Antiviral therapy.

Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART).

C. Torti, G. Carosi, P. Airó, 2004, Viral immunology.

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study

A. d’Arminio Monforte, E. Buscarini, P. Lampertico, 2021, Hepatology communications.

Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

A. d’Arminio Monforte, S. Lazzaroni, M. Valsecchi, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report

C. Torti, I. Izzo, M. Gambarotti, 2007, Journal of medical case reports.

Comment on: residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.

F. Maggiolo, G. Cologni, L. Soavi, 2012, The Journal of antimicrobial chemotherapy.

Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV

C. Torti, G. Carosi, M. Puoti, 2008, Antiviral therapy.

755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS

M. Colombo, G. Spinzi, M. Strazzabosco, 2013 .

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort

S. Leone, F. Maggiolo, D. Ripamonti, 2011, Infection.

Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received

S. Di Giambenedetto, C. Torti, M. Fabbiani, 2012, AIDS Research and Therapy.

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

M. Prosperi, I. Frank, C. Torti, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis

R. Idilman, C. Yurdaydın, G. Spinzi, 2014 .

Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAART-Treated Patients and Risk of Virological Failure

S. Leone, F. Maggiolo, A. Callegaro, 2012, Journal of acquired immune deficiency syndromes.

Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral Hepatitis

G. Filice, M. Colombo, L. Minoli, 2016 .

Influence of Folate Serum Concentration on Plasma Homocysteine Levels in HIV-Positive Patients Exposed to Protease Inhibitors Undergoing HAART

C. Torti, G. Carosi, F. Moretti, 2006, Annals of Nutrition and Metabolism.

Updated prevalence of genotypic resistance among HIV‐1 positive patients naïve to antiretroviral therapy: a single center analysis

Carlo Torti, C. Torti, I. Izzo, 2008, Journal of medical virology.

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

A. Antinori, A. De Luca, C. Mussini, 2011, BMC infectious diseases.